You can download the 2018 agenda here:
|12:30 - 1:00|| Registration
MC: Dr. Cheng-Chiu Huang
|1:00 - 1:10|| Opening Remarks |
Chih-Cheng Yeh, Director of Science and Technology Division, Taipei Economic and Cultural Office
|1:10 - 2:00|| Topic: Engineering Living Therapeutics and Diagnostics|
Dr. Tim Lu, Associate Professor, MIT
|2:00 - 2:40|| Topic: A New Way to Look at Cancer |
Peter Lu, CEO, Arbor Vita Corporation
|2:30 - 3:10|| Topic: NGS Advancements for Immuno-oncology and Liquid Biopsy|
|3:20 - 3:40||Coffee Break|
|3:40 - 4:20|| Topic: Machine Learning Driven Computational Pathology for Cancer Diagnostics |
Dr. Humayum Irshad, Lead Scientist for Machine Learning and Computer Vision, Figure Eight
|4:20 - 5:00|| Merging Functional Genomics and AI for Cancer Therapeutics and Detection |
Chun-Hao Huang, Co-Founder & CEO, Clinicai
|5:00 - 5:40|| Panel Discussion |
|5:40 - 5:50|| Closing Remarks |
|5:50 - 6:30|| Reception |
Timothy Lu, PhD
Timothy Lu is an Associate Professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Tim graduated with his SB and MEng from MIT, and his MD/PhD from the Harvard-MIT Health Sciences and Technology program. He is a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies innovating new diagnostic and therapeutic technologies for human health, including Sample6, Senti Biosciences, Synlogic, Eligo Biosciences, BiomX, and Engine Biosciences.
Tim’s research at MIT focuses on engineering platforms for computing and memory in living cells and applying these to create adaptive medicines as next-generation cell and gene therapies for important human diseases. His work also includes developing novel technology platforms to interrogate and correct diseased cell states. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.
Humayun Irshad, PhD
A computer scientist with expertise’s in machine learning, deep learning, computer vision, medical image analysis and statistical methods. He is developing computational techniques to combine computer vision, machine learning and statistical approaches for automated object detection, segmentation and classification in 2D and 3D images and application ranging from medical, retail, self-driving car, satalite, drones, etc. He has completed a 3 years PostDoc at Harvard Medical School and also received a PhD in Computer Science from University of Grenoble France, where he developed machine learning and deep learning techniques include region of interest detection and classification, and nuclei and gland detection, segmentation and classification in 2D and 3D histopathological images (H&E stained, IHC stained and fluorescence images).
Chun-Hao Huang, PhD
Chun-Hao is a cancer biologist, genetic engineer and AI entrepreneur. He received his postdoctoral training under the mentorship of HHMI investigator Professor Jennifer Doudna at UC Berkeley, and Ph.D. in HHMI investigator Professor Scott Lowe’s Lab at Memorial Sloan-Kettering Cancer Center & Weill Cornell Medicine. He pioneered the establishment of fast and flexible genetically engineered preclinical mouse models using gene silencing and editing technologies, and led the discovery of therapeutic strategies for treating liver cancer and inflammatory bowel disease. He also invented methods to identify disease biomarkers, and applied machine learning to the study of genes.
Chun-Hao is UN’s Sustainable Development Goals Talent and Winner of the UNLEASH Innovation Lab, Fellow of the 64th Lindau Nobel Laureate Meeting, 2018 MIT Technology Review Innovator Under 35 Asia Pacific, and co-organizer of the 2018 SingularityU APAC Global Impact Challenge. He received a Google and Genentech Scholarship to attend Singularity University in NASA Ames to co-found Clinicai, a startup that brings bio and space technologies to our daily life for continuously health monitoring and non-invasive early cancer detection.
Cheng-Chiu Huang, PhD
Coming to the US from Yilan, Taiwan, Cheng-Chiu received his Ph.D. in Developmental Biology at Baylor College of Medicine. He then had postdoctoral training in Neurobiology, Anesthesiology, and Dermatology at Howard Hughes Medical Institute - Janelia Research Campus and Washington University in St. Louis.
Cheng-Chiu is with an early discovery team at Merck working on sensory, autonomic, and muscle physiology. He managed a pipeline project on postsurgical analgesia at TLC Biopharmaceuticals toward successful IND application. He has also led several academic programs on peripheral sensory neuropathy, ocular and skin allergy, and neural circuitry formation, using a wide variety of molecular, genetic, and pharmacological approaches.
Dr. Lu founded Arbor Vita Corporation in 1998 to develop novel therapeutics and diagnostics in oncology for clinical use.
Prior to Arbor Vita, he was on the faculty at Stanford University School of Medicine and directed the Psoriasis Treatment Center. He founded the Papua New Guinea Medical Project, the longest running international medicine program at Stanford.
Dr. Lu received a M.S. (Micro/Immuno) and M.D. (with honors) from the University of Washington and a B.S. in biology from the California Institute of Technology (Caltech). He completed his residency in Dermatology at Stanford University School of Medicine and fellowship with Dr. Mark Davis at Howard Hughes Medical